Cited by 36

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function

Gao, Feng, Ihn, Hansel E., Medina, Marisa W., Krauss, Ronald M.·2013·Human Molecular Genetics

Abstract

A common synonymous single nucleotide polymorphism in exon 12 of the low-density lipoprotein receptor (LDLR) gene, rs688, has been associated with increased plasma total and LDL cholesterol in several populations. Using immortalized lymphoblastoid cell lines from a healthy study population, we confirmed an earlier report that the minor allele of rs688 is associated with increased exon 12 alternative splicing (P < 0.05) and showed that this triggered nonsense-mediated decay (NMD) of the alternatively spliced LDLR mRNA. However, since synonymous single nucleotide polymorphisms may influence structure and function of the encoded proteins by co-translational effects, we sought to test whether rs688 was also functional in the full-length mRNA. In HepG2 cells expressing LDLR cDNA constructs engineered to contain the major or minor allele of rs688, the latter was associated with a smaller amount of LDLR protein at the cell surface (-21.8 ± 0.6%, P = 0.012), a higher amount in the lysosome fraction (+25.7 ± 0.3%, P = 0.037) and reduced uptake of fluorescently labeled LDL (-24.3 ± 0.7%, P < 0.01). Moreover, in the presence of exogenous proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces cellular LDL uptake by promoting lysosomal degradation of LDLR, the minor allele resulted in reduced capacity of a PCSK9 monoclonal antibody to increase LDL uptake. These findings are consistent with the hypothesis that rs688, which is located in the β-propeller region of LDLR…

Overview

Integrity signals

Registry

Crossref · 10.1093/hmg/dds559

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. Goldstein, 1982, Receptor-mediated endocytosis and the cellular uptake of low density lipoprotein, Ciba Foundation symposium, 77
  2. Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311 · DOI · Paper page
  3. Teslovich, 2010, Biological, clinical and population relevance of 95 loci for blood lipids, Nature, 466, 707, 10.1038/nature09270 · DOI · Paper page
  4. Boright, 1998, Association and linkage of LDLR gene variation with variation in plasma low density lipoprotein cholesterol, Journal of human genetics, 43, 153, 10.1007/s100380050060 · DOI
  5. Fu, 2001, A common mutation of low-density lipoprotein receptor gene is associated with essential hypertension among Japanese, Journal of human hypertension, 15, 125, 10.1038/sj.jhh.1001132 · DOI
  6. Schaefer, 1994, Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study, Arterioscler Thromb, 14, 1105, 10.1161/01.ATV.14.7.1105 · DOI
  7. Zhu, 2007, A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Hum Mol Genet, 16, 1765, 10.1093/hmg/ddm124 · DOI
  8. Zou, 2008, Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease, Human molecular genetics, 17, 929, 10.1093/hmg/ddm365 · DOI · Paper page
  9. Sanchez-Sanchez, 2008, Nonsense-mediated decay: paving the road for genome diversification, Bioessays, 30, 926, 10.1002/bies.20825 · DOI
  10. Wen, 2008, Nonsense-mediated mRNA decay, Biochemical Society transactions, 36, 514, 10.1042/BST0360514 · DOI
  11. Waldman, 2011, Selection for translation efficiency on synonymous polymorphisms in recent human evolution, Genome biology and evolution, 3, 749, 10.1093/gbe/evr076 · DOI
  12. Xu, 2010, Screening of Kozak-motif-located SNPs and analysis of their association with human diseases, Biochemical and biophysical research communications, 392, 89, 10.1016/j.bbrc.2010.01.002 · DOI
  13. Nackley, 2009, Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs, PloS one, 4, 10.1371/journal.pone.0005237 · DOI
  14. Lee, 2008, F-SNP: computationally predicted functional SNPs for disease association studies, Nucleic acids research, 36, D820, 10.1093/nar/gkm904 · DOI
  15. Kimchi-Sarfaty, 2007, A "silent" polymorphism in the MDR1 gene changes substrate specificity, Science, 315, 525, 10.1126/science.1135308 · DOI · Paper page
  16. Wang, 2005, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability, Pharmacogenetics and genomics, 15, 693, 10.1097/01.fpc.0000178311.02878.83 · DOI
  17. Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proceedings of the National Academy of Sciences of the United States of America, 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
  18. Beglova, 2004, Structural features of the low-density lipoprotein receptor facilitating ligand binding and release, Biochemical Society transactions, 32, 721, 10.1042/BST0320721 · DOI
  19. Schell, 2002, Integration of splicing, transport and translation to achieve mRNA quality control by the nonsense-mediated decay pathway, Genome biology, 3, 10.1186/gb-2002-3-3-reviews1006 · DOI
  20. Tveten, 2012, Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification, Human molecular genetics, 21, 1402, 10.1093/hmg/ddr578 · DOI · Paper page
  21. Martinelli, 2010, Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile, Blood, 116, 5688, 10.1182/blood-2010-03-277079 · DOI
  22. Linsel-Nitschke, 2008, Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease–a Mendelian Randomisation study, PloS one, 3, 10.1371/annotation/9f64c41a-8cf6-40f2-8988-0d48b04dd8cb · DOI
  23. Holla, 2009, Nonsense-mediated decay of human LDL receptor mRNA, Scandinavian journal of clinical and laboratory investigation, 69, 409, 10.1080/00365510802707163 · DOI
  24. Angov, 2011, Codon usage: nature's roadmap to expression and folding of proteins, Biotechnology journal, 6, 650, 10.1002/biot.201000332 · DOI
  25. Bartoszewski, 2010, A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein, The Journal of biological chemistry, 285, 28741, 10.1074/jbc.M110.154575 · DOI
  26. Tsai, 2008, Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima, Journal of molecular biology, 383, 281, 10.1016/j.jmb.2008.08.012 · DOI
  27. Bulmer, 1987, Coevolution of codon usage and transfer RNA abundance, Nature, 325, 728, 10.1038/325728a0 · DOI
  28. Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH, EMBO reports, 12, 1300, 10.1038/embor.2011.205 · DOI · Paper page
  29. Zhang, 2012, An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes, International journal of biological sciences, 8, 310, 10.7150/ijbs.3524 · DOI
  30. Heeren, 1999, Nonphysiological overexpression of low-density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesteryl ester crystals in vitro, J Mol Med (Berl), 77, 735, 10.1007/s001099900045 · DOI
  31. Roth, 2012, Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia, The New England journal of medicine, 10.1056/NEJMoa1201832 · DOI
  32. Pressman, 1991, Epstein-Barr virus transformation of cryopreserved lymphocytes: prolonged experience with technique, American journal of human genetics, 49, 467
  33. Medina, 2008, Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin, Circulation, 118, 355, 10.1161/CIRCULATIONAHA.108.773267 · DOI
  34. Medina, 2011, Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PloS one, 6, 10.1371/journal.pone.0019420 · DOI
  35. Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proceedings of the National Academy of Sciences of the United States of America, 106, 9820, 10.1073/pnas.0903849106 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Gao, F., Ihn, H. E., Medina, M. W., & Krauss, R. M.
Venue
Human Molecular Genetics
Published
2013-01-07
Volume
22
Issue
7
Pages
1424-1431
ISSN
  • 1460-2083
  • 0964-6906
Cited by
36
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review